* Lucira Health Inc LHDX.OQ LHDX.O is expected to report
results on November 11.
* The Emeryville, California-based company is expected to report
revenue of $18.3 million, according to the mean estimate from 3
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Lucira Health Inc is
for a loss of 51 cents per share.
* The current average analyst rating on the shares is "hold" and
the breakdown of recommendations is no "strong buy" or "buy," 2
"hold" and 1 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the
last three months.
* Wall Street's median 12-month price target for Lucira Health
Inc is $7.25, about 11% above its last closing price
of $6.45.
* Previous quarterly performance (using preferred earnings
measure in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Jun. 30 2021 -0.32 -0.32 -0.38 Missed -18.7
Mar. 31 2021 -0.33 -0.33 -0.54 Missed -63.6
This summary was machine generated November 10 at 02:32 GMT.
All figures in US dollars unless otherwise stated